{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=tocilizumab+IV", "query": { "intervention": "tocilizumab IV" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 101, "total_pages": 11, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=tocilizumab+IV&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-20T08:05:25.416Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05129280", "title": "A Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-tumor Activity of RO7444973 in Participants With Unresectable and/or Metastatic MAGE-A4-positive Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "RO7444973", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2022-01-25", "completion_date": "2023-07-12", "has_results": false, "last_update_posted_date": "2023-08-04", "last_synced_at": "2026-09-20T08:05:25.416Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05129280" }, { "nct_id": "NCT07281027", "title": "COMparison Between Anakinra and Tocilizumab in NORSE - \"COMBAT-NORSE\"", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "New Onset Refractory Status Epilepticus", "New-Onset Refractory Status Epilepticus", "Febrile Infection-Related Epilepsy Syndrome (FIRES)" ], "interventions": [ { "name": "Anakinra", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" }, { "name": "Standard medical treatment", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": 438, "start_date": "2026-12-01", "completion_date": "2030-09-30", "has_results": false, "last_update_posted_date": "2026-08-19", "last_synced_at": "2026-09-20T08:05:25.416Z", "location_count": 25, "location_summary": "Phoenix, Arizona • Aurora, Colorado • New Haven, Connecticut + 17 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07281027" }, { "nct_id": "NCT03075696", "title": "A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Hodgkin's Lymphoma" ], "interventions": [ { "name": "Glofitamab", "type": "DRUG" }, { "name": "Obinutuzumab", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 940, "start_date": "2017-02-21", "completion_date": "2029-03-30", "has_results": false, "last_update_posted_date": "2026-07-29", "last_synced_at": "2026-09-20T08:05:25.416Z", "location_count": 6, "location_summary": "Ann Arbor, Michigan • St Louis, Missouri • New York, New York + 2 more", "locations": [ { "city": "Ann Arbor", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03075696" }, { "nct_id": "NCT06624085", "title": "A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "Glofitamab", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" }, { "name": "Obinutuzumab", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2025-04-28", "completion_date": "2027-03-22", "has_results": false, "last_update_posted_date": "2026-09-08", "last_synced_at": "2026-09-20T08:05:25.416Z", "location_count": 17, "location_summary": "La Jolla, California • Laguna Hills, California • Newport Beach, California + 14 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Laguna Hills", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06624085" }, { "nct_id": "NCT00862758", "title": "Request for Single Patient IND for Compassionate/Emergency Use of Tocilizumab", "overall_status": "NO_LONGER_AVAILABLE", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Juvenile Idiopathic Arthritis" ], "interventions": [ { "name": "Tocilizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Oklahoma", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "11 Years", "maximum_age": "12 Years", "sex": "MALE", "summary": "11 Years to 12 Years · Male only" }, "enrollment_count": null, "start_date": "2009-02", "completion_date": "2010-10", "has_results": false, "last_update_posted_date": "2013-12-10", "last_synced_at": "2026-09-20T08:05:25.416Z", "location_count": 1, "location_summary": "Oklahoma City, Oklahoma", "locations": [ { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT00862758" }, { "nct_id": "NCT01007435", "title": "A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Tocilizumab", "type": "DRUG" }, { "name": "Placebo to tocilizumab", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Placebo to methotrexate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1162, "start_date": "2009-10-31", "completion_date": "2014-01-28", "has_results": true, "last_update_posted_date": "2017-07-26", "last_synced_at": "2026-09-20T08:05:25.416Z", "location_count": 61, "location_summary": "Anniston, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 54 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Tuscaloosa", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01007435" }, { "nct_id": "NCT04616248", "title": "In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Anatomic Stage IV Breast Cancer AJCC v8", "Metastatic Breast Carcinoma", "Prognostic Stage IV Breast Cancer AJCC v8", "Unresectable Breast Carcinoma", "Metastatic Melanoma", "Unresectable Melanoma", "Cutaneous Squamous Cell Carcinoma", "Merkel Cell Carcinoma", "Soft Tissue Sarcoma", "Bone Sarcoma", "Sarcoma,Soft Tissue", "Sarcoma of Bone", "Basal Cell Carcinoma" ], "interventions": [ { "name": "Anti-CD40 Agonist Monoclonal Antibody CDX-1140", "type": "BIOLOGICAL" }, { "name": "Poly ICLC", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Recombinant Flt3 Ligand", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2023-01-09", "completion_date": "2028-01-09", "has_results": false, "last_update_posted_date": "2026-06-18", "last_synced_at": "2026-09-20T08:05:25.416Z", "location_count": 2, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04616248" }, { "nct_id": "NCT04338685", "title": "A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Carcinoma, Hepatocellular", "Biliary Tract Cancer", "Secondary Liver Cancer", "Liver Metastases" ], "interventions": [ { "name": "RO7119929", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 55, "start_date": "2020-07-16", "completion_date": "2023-01-09", "has_results": true, "last_update_posted_date": "2024-12-09", "last_synced_at": "2026-09-20T08:05:25.416Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04338685" }, { "nct_id": "NCT04375228", "title": "Study of Rituximab or Tocilizumab for Patients With Steroid-Dependent Immune-Related Adverse Events (irAEs)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Immune-related Adverse Events", "Advanced Solid Tumor" ], "interventions": [ { "name": "Rituximab", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2020-09-25", "completion_date": "2026-12", "has_results": true, "last_update_posted_date": "2026-08-03", "last_synced_at": "2026-09-20T08:05:25.416Z", "location_count": 3, "location_summary": "Baltimore, Maryland • New York, New York", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04375228" }, { "nct_id": "NCT00106574", "title": "A Study to Assess the Effect of Tocilizumab + DMARD Therapy on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "tocilizumab [RoActemra/Actemra]", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1220, "start_date": "2005-04", "completion_date": "2007-12", "has_results": false, "last_update_posted_date": "2016-11-02", "last_synced_at": "2026-09-20T08:05:25.416Z", "location_count": 76, "location_summary": "Mesa, Arizona • Paradise Valley, Arizona • Peoria, Arizona + 71 more", "locations": [ { "city": "Mesa", "state": "Arizona" }, { "city": "Paradise Valley", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00106574" } ] }